Cargando…
181. Evaluation of a Pilot Initiative for Tracking and Monitoring Indications Associated With Antibiotic Orders
BACKGROUND: The Christiana Care Antimicrobial Stewardship Program developed a pilot initiative for tracking and monitoring antibiotic utilization across the health system. This initiative aligns with the Joint Commission’s elements of performance, which calls for tracking and reporting of antibiotic...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253619/ http://dx.doi.org/10.1093/ofid/ofy210.194 |
_version_ | 1783373537955807232 |
---|---|
author | John, Jamie Harrington, Nicole Gardner, Julianne Dougherty, Jillian Walsh, Donna Dzuriak, Erin Drees, Marci Eppes, Stephen Kharidi, Sharath Cheung, Linda |
author_facet | John, Jamie Harrington, Nicole Gardner, Julianne Dougherty, Jillian Walsh, Donna Dzuriak, Erin Drees, Marci Eppes, Stephen Kharidi, Sharath Cheung, Linda |
author_sort | John, Jamie |
collection | PubMed |
description | BACKGROUND: The Christiana Care Antimicrobial Stewardship Program developed a pilot initiative for tracking and monitoring antibiotic utilization across the health system. This initiative aligns with the Joint Commission’s elements of performance, which calls for tracking and reporting of antibiotic prescribing, as well as the Centers for Medicare and Medicaid Services recommendations for documentation of antibiotic indication, dose, and duration with each order. A customized indication list in the order entry field was created for cefepime, ceftriaxone, levofloxacin, and ciprofloxacin orders. METHODS: A retrospective chart review of antibiotic indications was completed. A maximum of 50 orders per each antibiotic from December 31, 2017 to January 6, 2018 were randomly selected to be evaluated. The primary endpoint of our study was the percent of cases in which the indication was selected according to the true indication per chart review. Secondary endpoints included the percent of cases in which “other indication” was selected where an available indication was appropriate, percent of cases in which the appropriate dose and frequency were prescribed, and percent of cases in which the duration of therapy was appropriate for urinary tract infections (UTIs). RESULTS: A total of 540 orders were profiled between December 31, 2017 and January 6, 2018, of which 182 were reviewed. In regards to the accuracy of selected indication, 94% of cefepime, 88% of ceftriaxone, 78% of ciprofloxacin, and 89% of levofloxacin orders were considered appropriate. Dosing was most appropriate among ciprofloxacin orders (100%), followed by ceftriaxone (96%), cefepime (94%), and levofloxacin (74%). Frequency was most appropriate among ceftriaxone orders (98%), followed by ciprofloxacin (87%), levofloxacin (78%), and cefepime (74%). Duration of therapy was appropriate in greater than 90% of UTI orders. CONCLUSION: The pilot initiative for tracking and monitoring of antibiotic indications has allowed for enhanced transparency between providers regarding antimicrobial use. Further evaluation may provide greater understanding of antibiotic utilization and aid in identifying opportunities for improvements. DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6253619 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62536192018-11-28 181. Evaluation of a Pilot Initiative for Tracking and Monitoring Indications Associated With Antibiotic Orders John, Jamie Harrington, Nicole Gardner, Julianne Dougherty, Jillian Walsh, Donna Dzuriak, Erin Drees, Marci Eppes, Stephen Kharidi, Sharath Cheung, Linda Open Forum Infect Dis Abstracts BACKGROUND: The Christiana Care Antimicrobial Stewardship Program developed a pilot initiative for tracking and monitoring antibiotic utilization across the health system. This initiative aligns with the Joint Commission’s elements of performance, which calls for tracking and reporting of antibiotic prescribing, as well as the Centers for Medicare and Medicaid Services recommendations for documentation of antibiotic indication, dose, and duration with each order. A customized indication list in the order entry field was created for cefepime, ceftriaxone, levofloxacin, and ciprofloxacin orders. METHODS: A retrospective chart review of antibiotic indications was completed. A maximum of 50 orders per each antibiotic from December 31, 2017 to January 6, 2018 were randomly selected to be evaluated. The primary endpoint of our study was the percent of cases in which the indication was selected according to the true indication per chart review. Secondary endpoints included the percent of cases in which “other indication” was selected where an available indication was appropriate, percent of cases in which the appropriate dose and frequency were prescribed, and percent of cases in which the duration of therapy was appropriate for urinary tract infections (UTIs). RESULTS: A total of 540 orders were profiled between December 31, 2017 and January 6, 2018, of which 182 were reviewed. In regards to the accuracy of selected indication, 94% of cefepime, 88% of ceftriaxone, 78% of ciprofloxacin, and 89% of levofloxacin orders were considered appropriate. Dosing was most appropriate among ciprofloxacin orders (100%), followed by ceftriaxone (96%), cefepime (94%), and levofloxacin (74%). Frequency was most appropriate among ceftriaxone orders (98%), followed by ciprofloxacin (87%), levofloxacin (78%), and cefepime (74%). Duration of therapy was appropriate in greater than 90% of UTI orders. CONCLUSION: The pilot initiative for tracking and monitoring of antibiotic indications has allowed for enhanced transparency between providers regarding antimicrobial use. Further evaluation may provide greater understanding of antibiotic utilization and aid in identifying opportunities for improvements. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253619/ http://dx.doi.org/10.1093/ofid/ofy210.194 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts John, Jamie Harrington, Nicole Gardner, Julianne Dougherty, Jillian Walsh, Donna Dzuriak, Erin Drees, Marci Eppes, Stephen Kharidi, Sharath Cheung, Linda 181. Evaluation of a Pilot Initiative for Tracking and Monitoring Indications Associated With Antibiotic Orders |
title | 181. Evaluation of a Pilot Initiative for Tracking and Monitoring Indications Associated With Antibiotic Orders |
title_full | 181. Evaluation of a Pilot Initiative for Tracking and Monitoring Indications Associated With Antibiotic Orders |
title_fullStr | 181. Evaluation of a Pilot Initiative for Tracking and Monitoring Indications Associated With Antibiotic Orders |
title_full_unstemmed | 181. Evaluation of a Pilot Initiative for Tracking and Monitoring Indications Associated With Antibiotic Orders |
title_short | 181. Evaluation of a Pilot Initiative for Tracking and Monitoring Indications Associated With Antibiotic Orders |
title_sort | 181. evaluation of a pilot initiative for tracking and monitoring indications associated with antibiotic orders |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253619/ http://dx.doi.org/10.1093/ofid/ofy210.194 |
work_keys_str_mv | AT johnjamie 181evaluationofapilotinitiativefortrackingandmonitoringindicationsassociatedwithantibioticorders AT harringtonnicole 181evaluationofapilotinitiativefortrackingandmonitoringindicationsassociatedwithantibioticorders AT gardnerjulianne 181evaluationofapilotinitiativefortrackingandmonitoringindicationsassociatedwithantibioticorders AT doughertyjillian 181evaluationofapilotinitiativefortrackingandmonitoringindicationsassociatedwithantibioticorders AT walshdonna 181evaluationofapilotinitiativefortrackingandmonitoringindicationsassociatedwithantibioticorders AT dzuriakerin 181evaluationofapilotinitiativefortrackingandmonitoringindicationsassociatedwithantibioticorders AT dreesmarci 181evaluationofapilotinitiativefortrackingandmonitoringindicationsassociatedwithantibioticorders AT eppesstephen 181evaluationofapilotinitiativefortrackingandmonitoringindicationsassociatedwithantibioticorders AT kharidisharath 181evaluationofapilotinitiativefortrackingandmonitoringindicationsassociatedwithantibioticorders AT cheunglinda 181evaluationofapilotinitiativefortrackingandmonitoringindicationsassociatedwithantibioticorders |